Online inquiry

IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1106MR)

This product GTTS-WQ1106MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MAPT gene. The antibody can be applied in Progressive supranuclear palsy (PSP) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001123066.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4137
UniProt ID P10636
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ1106MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8283MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HM10560A
GTTS-WQ15914MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XOMA 052
GTTS-WQ12673MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ7608MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ1978MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AGS-15E
GTTS-WQ13451MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRS-343
GTTS-WQ13287MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06523435
GTTS-WQ5241MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CB 2679d
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW